Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles (Q43274051)

18 November 2017

Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles (English)

1 reference

18 November 2017

Y J Ioffe

1

1 reference

18 November 2017

A J Li

2

1 reference

18 November 2017

C S Walsh

3

1 reference

18 November 2017

B Y Karlan

4

1 reference

18 November 2017

R Leuchter

5

1 reference

18 November 2017

C Forscher

6

1 reference

18 November 2017

I Cass

7

1 reference

18 November 2017

language of work or name

English

0 references

publication date

20 September 2009

1 reference

18 November 2017

1 reference

18 November 2017

115

1 reference

18 November 2017

3

1 reference

18 November 2017

466-471

1 reference

Uterine sarcomas: A clinicopathologic study, 1965–1981

18 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Sarcoma of the uterus. A clinical and pathologic study of 177 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Endometrial cancer state of the science meeting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

The management of patients with uterine sarcoma: a debated clinical challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Hormonal therapy of endometrial stromal sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Hormonal therapies and gynaecological cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Aromatase cytochrome P450 and estrogen and progesterone receptors in uterine sarcomas: correlation with clinical parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Uterine sarcoma: steroid receptors and response to hormonal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Predictive markers in breast and other cancers: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Estrogen and progesterone receptors expression in uterine malignant smooth muscle tumors: correlation with clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Low-grade endometrial stromal sarcoma: hormonal aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

Discordant responses to progestin in a patient with uterine low-grade smooth-muscle tumors metastatic to the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

7 January 2021

Uterine leiomyosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.08.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2009.08.014

1 reference

release_3dkz7d4lxncmfaegwar6j5de6i

18 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3dkz7d4lxncmfaegwar6j5de6i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference